STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator. The inventions relate to the medical use of GT-002 in psychiatric disorders..

斯德哥尔摩，2024年3月18日/PRNewswire/--Gabather AB（纳斯达克第一北方增长市场：GABA）今天报道，两项新的美国临时专利申请基于EEG/fMRI目标参与研究的新发现，GT-002是一种选择性阳性变构GABAA受体调节剂。这些发明涉及GT-002在精神疾病中的医疗用途。。

The claims based on inventions from the results from our EEG/fMRI target engagement study are both novel and unexpected and will strengthen Gabather's intellectual property right (IPR) position in the field of GABAA receptor modulators, and the medical use of GT-002. Our IPR strategy is to build layers of patents around our drug products, generating a strong and attractive IPR position for the products that generates an extended patent protection of the drug product.

基于我们的脑电图/功能磁共振成像目标参与研究结果的发明的索赔既新颖又出乎意料，将加强加巴瑟在GABAA受体调节剂领域的知识产权（IPR）地位，以及GT-002的医疗用途。我们的知识产权战略是围绕我们的药品建立多层专利，为产品创造强大而有吸引力的知识产权地位，从而扩大药品的专利保护。

Gabather has an active portfolio of patents and patent applications covering key products and methods that create significant value to the company, giving Gabather the freedom to operate, product differentiation, as well as a strong negotiation position in potential agreement negotiations..

加巴瑟拥有活跃的专利和专利申请组合，涵盖为公司创造重大价值的关键产品和方法，使加巴瑟拥有运营自由、产品差异化以及在潜在协议谈判中的强大谈判地位。。

'When approved by USPTO these patent's will further strengthen our drug products and market position, giving Gabather a strong competitive advantage in providing the next generation neuropsychiatric drugs to the patients. We will move forward into clinical trials in patients and identify the right partner for the continued development of GT-002' says Michael-Robin Witt, CEO of Gabather AB..

“当USPTO批准时，这些专利将进一步加强我们的药品和市场地位，使加巴瑟在为患者提供下一代神经精神药物方面具有强大的竞争优势。Gabather AB首席执行官迈克尔·罗宾·维特（MichaelRobinWitt）表示，我们将推进患者的临床试验，并为GT-002的持续发展确定正确的合作伙伴。。

About GT-002

关于GT-002

GT-002 is a small molecule GABAA receptor Positive Allosteric Modulator (PAM) eliciting both tonic and phasic inhibitory currents. GT-002 improves learning and memory in preclinical models. It restores ketamine induced cognitive deficits in the discrimination learning task model, and inhibits the behavioural effects induced by phencyclidine in the in-vivo model of schizophrenia.

GT-002是一种小分子GABAA受体阳性变构调节剂（PAM），可引起强直和相位抑制电流。GT-002改善了临床前模型中的学习和记忆。它在辨别学习任务模型中恢复氯胺酮诱导的认知缺陷，并在精神分裂症的体内模型中抑制苯环利定诱导的行为效应。

GT-002 has been shown to be anxiolytic and to promote social interaction in rats. GT-002 targets a novel binding site on GABAA receptors, different from benzodiazepines (BZD), and has not shown any of the side effects known for BZD. Long-term treatment (28 days) with GT-002 has not shown any withdrawal symptoms upon cessation of treatment both in mice and dogs, indicating no drug abuse liability associated with this drug candidate.

GT-002已被证明具有抗焦虑作用，并可促进大鼠的社交互动。GT-002靶向GABAA受体上的新结合位点，不同于苯二氮卓类（BZD），并且没有显示出BZD已知的任何副作用。GT-002的长期治疗（28天）在小鼠和狗停止治疗后均未显示任何戒断症状，表明与该候选药物无关的药物滥用责任。

GT-002 has completed 3 phase I clinical trials in healthy volunteers. Both single ascending dose (SAD) and multiple ascending dose (MAD) studies have been completed. The results from these studies show that GT-002 is safe and well tolerated and that it has excellent pharmacokinetics, allowing for once-a-day oral dosing.

GT-002已在健康志愿者中完成了3项I期临床试验。单次递增剂量（SAD）和多次递增剂量（MAD）研究均已完成。这些研究的结果表明，GT-002安全且耐受性良好，并且具有良好的药代动力学，可以每天口服一次。

An EEG/fMRI target engagement study in healthy volunteers aimed to determine the effects of GT-002 on brain activity across different brain regions and neuronal networks has recently been completed..

最近完成了一项针对健康志愿者的脑电图/功能磁共振成像目标参与研究，旨在确定GT-002对不同大脑区域和神经元网络大脑活动的影响。。

Contact InformationMichael-Robin Witt, CEOPhone: 073-687 28 39E-mail: mrw@gabather.com

联系信息首席执行官Michael Robin Witt电话：073-687 28 39电子邮件：mrw@gabather.com

About Gabather

关于加巴瑟

Gabather is a clinical-stage pharmaceutical company aiming to transform the treatment of neuropsychiatric disorders. The Company was founded as a response to the significant unmet need and lack of innovative therapeutics in the mental health treatment landscape. Gabather is dedicated to developing innovative therapeutics for the treatment of a broad range of neuropsychiatric disorders.

加巴瑟是一家临床阶段制药公司，旨在改变神经精神疾病的治疗方法。该公司的成立是为了应对心理健康治疗领域的重大未满足需求和缺乏创新疗法。加巴瑟致力于开发创新疗法，用于治疗广泛的神经精神疾病。

The goal is to accelerate the development of new groundbreaking medicines to achieve clinically meaningful therapies for the patients..

目标是加速开发新的突破性药物，为患者实现具有临床意义的治疗。。

For more information, please visit: www.gabather.com

有关更多信息，请访问：www.gabather.com

Certified AdviserCorpura Fondkommission ABPhone: +4672-252 34 51Email: ca@corpura.se www.corpura.se

认证顾问公司Fondkommission ABPhone：+4672-252 34 51电子邮件：ca@corpura.sewww.corpura.se

Forward-looking statement

前瞻性声明

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty.

本新闻稿包含前瞻性陈述，构成对未来的主观估计和预测。关于未来的评估只有在做出之日才有效，就其性质而言，类似于生物技术领域的研究和开发工作，与风险和不确定性有关。

In light of this, actual outcomes may differ substantially from what is described in this press release. Gabather is listed on First North Growth Market and Corpura Fondkommission AB is Certified Advisor..

有鉴于此，实际结果可能与本新闻稿中描述的结果有很大不同。Gabather在First North Growth Market上市，Corpura Fondkommission AB是认证顾问。。

This information was brought to you by Cision http://news.cision.com

此信息由Cision提供给您http://news.cision.com

https://news.cision.com/gabather-ab/r/gabather-files-two-new-patent-applications-to-secure-novel-findings-on-the-effects-of-gt-002-for-the,c3946912

https://news.cision.com/gabather-ab/r/gabather-files-two-new-patent-applications-to-secure-novel-findings-on-the-effects-of-gt-002-for-the，c3946912

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Public/11735/3946912/b5e635e909a537a0.pdf

https://mb.cision.com/Public/11735/3946912/b5e635e909a537a0.pdf

PM patent application 2024-03-18

PM专利申请2024-03-18